Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration
Elizabeth J. Phillips, Simon A. Mallal
Elizabeth J. Phillips, Simon A. Mallal
Published May 21, 2018
Citation Information: J Clin Invest. 2018;128(7):2746-2749. https://doi.org/10.1172/JCI121525.
View: Text | PDF
Commentary

Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration

  • Text
  • PDF
Abstract

The discovery of HLA-B*57:01–associated abacavir hypersensitivity is a translational success story that eliminated adverse reactions to abacavir through pretreatment screening and defined a mechanistic model of an altered peptide repertoire. In this issue of the JCI, Cardone et al. have developed an HLA-B*57:01–transgenic mouse model and demonstrated that CD4+ T cells play a key role in mediating tolerance to the dramatically altered endogenous peptide repertoire induced by abacavir and postulate a known mechanism by which CD4+ T cells suppress DC maturation. This report potentially explains why 45% of HLA-B*57:01 carriers tolerate abacavir and provides a framework for future studies of HLA-restricted, T cell–mediated drug tolerance and hypersensitivity.

Authors

Elizabeth J. Phillips, Simon A. Mallal

×

Figure 1

Model of the mechanism of tolerance or hypersensitivity to abacavir in HLA-B*57:01–Tg mice.

Options: View larger image (or click on image) Download as PowerPoint
Model of the mechanism of tolerance or hypersensitivity to abacavir in H...
Model of the mechanism of tolerance or hypersensitivity to abacavir in HLA-B*57:01–Tg mice. Abacavir binds noncovalently to residues on the floor of the peptide-binding groove of the HLA-B*57:01 molecule and the overlying endogenous peptide, dramatically altering the repertoire of endogenous peptides presented to early-responding CD44hiCD62LhiCD8+ Tcm cells (see inset). CD4+ T cell depletion results in the maturation of DCs to a CD86hiCD80hiPD-L1hi phenotype that is capable of costimulation and induction of effector CD8+ T cells that can home to the skin and induce hypersensitivity. Without CD4+ T cell depletion, DCs remain in an immature state (CD86loCD80loPD-L1lo), and the mouse remains tolerant to the altered peptide repertoire. Tcm, T central memory cell; TCR, T cell receptor.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts